Abstract
Acinetobacter baumannii is a Gram-negative bacterium that causes nosocomial infections worldwide, with recent prevalence and higher frequency in wounded military personnel. Four A. baumannii strains from the Walter Reed Army Medical Center (WRAMC) isolated between 2008 and 2009 were sequenced, representing diverse, multidrug-resistant isolates from osteomyelitis or septic patients.
GENOME ANNOUNCEMENT
Acinetobacter baumannii is a nonfermentative, Gram-negative coccobacillus that is the etiological agent of nosocomial infections resulting in septicemia, meningitis, endocarditis, pneumonia, and wound and urinary tract infections (7, 8, 10). The rapid development of antimicrobial resistance and nosocomial spread of this emerging pathogen have elicited great interest (5, 7, 8). A. baumannii isolates can typically be characterized into three identifiable clonal clusters, termed international clonal complexes I to III (4, 6, 9). In previous studies, U.S. military personnel have had representatives from each clonal complex (11, 13). The isolates sequenced for this report were part of a larger diversity set of A. baumannii isolates from 2005 to 2010 at the Walter Reed Army Medical Center (WRAMC) (our unpublished data).
A total of four strains were chosen, as they represented one of each clonal group and an outlier group based on pulsed-field gel electrophoresis (PFGE), multiplex PCR, and multilocus sequence type (MLST) analysis (http://www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.html), had different isolation sites (osteomyelitis of the tibia or ischium or blood), and had diverse phenotypes and virulence profiles (our unpublished data). The four strains were isolated within a year's time (2008 to 2009), determined to be multidrug resistant (MDR), and were obtained from the Multidrug-Resistant Organism Repository and Surveillance Network (MRSN). They are designated AB4857 (MRSN939), AB5075 (MRSN959), AB5256 (MRSN961), and AB5711 (MRSN1310).
Genomic DNA was prepared with the PureLink genomic DNA minikit (Invitrogen) according to the manufacturer's instructions and subjected to sequencing on a 454 GS-FLX Titanium system (454 Life Science Corporation) maintained at the University of Maryland School of Medicine, Institute for Genome Sciences, Genome Resource Center (http://www.igs.umaryland.edu/). Paired-end libraries with 3-kb inserts were sequenced for each of the isolates, yielding >320,000 reads for each isolate (range, 322,062 to 385,454 reads/isolate) and an average read size of 356.4 bp (range, 342.9 to 370.4); this results in ∼24.8-fold coverage for each genome (range, 22.67 to 26.0). Assembly was performed using the Newbler software, which resulted in an average of 47 contigs per isolate (range, 36 to 55) and 12.5 scaffolds (range, 11 to 14). The contig data were annotated using the cloud computing pipeline CloVR (3).
The GC content of the strains, 36.6% (range, 36.4 to 36.78%), is within the deviation for A. baumannii genomes (2, 12, 14). The numbers of predicted genes from the draft genomes were also similar to those of previously sequenced A. baumannii genomes, with 4,903 genes/genome (range, 4,673 to 5,084). Each of the strains had at least one contig that mapped to A. baumannii plasmids (1, 2, 12). Phylogenetically, these isolates are not similar to other isolates from a comparable isolation source (data not shown). No one functional group of genes was overrepresented in the annotation. Additionally, there were no large gene clusters that could account for the observed tissue tropism associated with the site of isolation in the human body. These facts taken together suggest that A. baumannii is a generalist pathogen that takes advantage of opportunities to invade the human body at certain locations (11, 12). Further analysis is required to determine how the gene differences are related to the observed phenotypes and will provide insight into A. baumannii pathogenesis.
Nucleotide sequence accession numbers.
The genome data have been deposited in GenBank under accession numbers AHAG00000000, AHAH00000000, AHAI00000000, and AHAJ00000000 for isolates AB4857, AB5075, AB5256, and AB5711, respectively.
ACKNOWLEDGMENTS
We thank AvidBiotics Inc. and, specifically, David Martin and Dean Scholl for their support with our A. baumannii research.
We acknowledge the NIH grant R43 AI088863-01 for the funding required for this project.
The findings and opinions expressed herein belong to the authors and do not necessarily reflect the official views of the WRAIR, the U.S. Army, or the Department of Defense.
REFERENCES
- 1. Adams MD, Chan ER, Molyneaux ND, Bonomo RA. 2010. Genomewide analysis of divergence of antibiotic resistance determinants in closely related isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 54:3569–3577 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Adams MD, et al. 2008. Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii. J. Bacteriol. 190:8053–8064 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Angiuoli SV, et al. 2011. CloVR: a virtual machine for automated and portable sequence analysis from the desktop using cloud computing. BMC Bioinformatics 12:356. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Dijkshoorn L, et al. 1996. Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods. J. Clin. Microbiol. 34:1519–1525 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Dijkshoorn L, Nemec A, Seifert H. 2007. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat. Rev. Microbiol. 5:939–951 [DOI] [PubMed] [Google Scholar]
- 6. Higgins PG, Dammhayn C, Hackel M, Seifert H. 2010. Global spread of carbapenem-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 65:233–238 [DOI] [PubMed] [Google Scholar]
- 7. Joly-Guillou ML. 2005. Clinical impact and pathogenicity of Acinetobacter. Clin. Microbiol. Infect. 11:868–873 [DOI] [PubMed] [Google Scholar]
- 8. Munoz-Price LS, et al. 2010. Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak. Infect. Control Hosp. Epidemiol. 31:1057–1062 [DOI] [PubMed] [Google Scholar]
- 9. Nemec A, et al. 2011. Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU). Res. Microbiol. 162:393–404 [DOI] [PubMed] [Google Scholar]
- 10. Ong CW, et al. 2009. Severe community-acquired Acinetobacter baumannii pneumonia: an emerging highly lethal infectious disease in the Asia-Pacific. Respirology 14:1200–1205 [DOI] [PubMed] [Google Scholar]
- 11. Petersen K, et al. 2011. Diversity and clinical impact of Acinetobacter baumannii colonization and infection at a military medical center. J. Clin. Microbiol. 49:159–166 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Sahl JW, et al. 2011. Genomic comparison of multi-drug resistant invasive and colonizing Acinetobacter baumannii isolated from diverse human body sites reveals genomic plasticity. BMC Genomics 12:291. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Turton JF, et al. 2006. Comparison of Acinetobacter baumannii isolates from the United Kingdom and the United States that were associated with repatriated casualties of the Iraq conflict. J. Clin. Microbiol. 44:2630–2634 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Vallenet D, et al. 2008. Comparative analysis of Acinetobacters: three genomes for three lifestyles. PLoS One 3:e1805. [DOI] [PMC free article] [PubMed] [Google Scholar]